Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

Latest News

Harvey Weinstein wants to move trial out of NYC

Aug 21, 2019

NEW YORK — A lawyer for Harvey Weinstein has asked that the disgraced movie mogul's upcoming criminal trial be moved out of New York City, saying he can't get a fair trial. In a longshot motion filed with the state appellate court on Friday, attorney Arthur Aidala suggested the trial be moved to upstate Albany County or Suffolk County on Long Island. Aidala cited the intense media coverage and the circuslike atmosphere surrounding Weinstein's past court appearances in Manhattan. The 67-year-old Weinstein is charged with raping a woman in 2013 and performing a forcible sex act on a different woman...

Cowboys' Elliott won't face criminal charge in Vegas scuffle

Aug 21, 2019

LAS VEGAS — Dallas Cowboys star running back Ezekiel Elliott won't face criminal charges after scuffling with a music festival security guard in Las Vegas. Prosecutor Steve Wolfson said Tuesday the findings of a police investigation "lacked prosecutorial merit." The NFL said last month that Elliott didn't violate league personal conduct rules and wouldn't face suspension. Elliott was handcuffed but not arrested after police said he pushed a security guard to the ground at the event last May at Las Vegas Motor Speedway. Cellphone video obtained by celebrity website TMZ showed an event staffer stumbling over a parking barrier after...

Paul Simon plants a tree at Hawaii forest preserve on Maui

Aug 21, 2019

AUWAHI, Hawaii — Musician Paul Simon joined environmentalists trying to reinvigorate a Hawaii forest on Maui and planted a tree during a ceremony, a report said. The singer-songwriter visited Auwahi Forest Restoration Project with volunteers who are trying to revive plant life in the area, The Honolulu Star-Advertiser reported Friday. Simon helped plant a lama tree and participated in chants with the group after a helicopter tour that he called "awe-inspiring" and "life-changing." Simon inserted the plant and a scroll into a hole before refilling the soil and speaking with group members. "To even sit with you guys and be...

Real Madrid opens Spanish league with 3-1 win over Celta

Aug 21, 2019

MADRID — Karim Benzema scored a goal and set up another as Real Madrid began its Spanish league campaign with a comfortable 3-1 win at Celta Vigo on Saturday. Toni Kroos and Lucas Vázquez also scored, as Madrid played most of the second half with 10 men following a red card to Luka Modric. Madrid was without new signing Eden Hazard because of an injury, and it was Gareth Bale — who many thought would be gone from the squad by now — who helped add the spark Madrid needed in attack. He set up Benzema's opening goal early in...

Without Messi, Barcelona loses 1st league opener in 10 years

Aug 21, 2019

MADRID — Barcelona lost its opening Spanish league match for the first time in a decade on Friday, falling at Athletic Bilbao 1-0 as Antoine Griezmann couldn't make up for Lionel Messi's absence. Veteran striker Aritz Aduriz scored from a spectacular overhead kick a minute after coming off the bench in the 88th minute, handing Barcelona the loss after 10 straight opening league wins. Griezmann, Barcelona's biggest offseason signing, was held scoreless in his competitive debut after joining from rival Atlético Madrid for 120 million euros ($133 million). It was a lackluster performance for the France forward whose only significant...

About Us

E-Stardom is the exclusive online news network for breaking entertainment news. We bring to you the premium coverage and fashion tips to your favorite celebrity style. Get your daily celebrity news fix only here in E-Stardom.

Contact us: sales[at]e-stardom.com

Subscribe Now!